VTYX
Ventyx Biosciences, Inc. [VTYX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
VTYX Stock Summary
Top 10 Correlated ETFs
VTYX
Top 10 Correlated Stocks
VTYX
In the News
Ventyx Biosciences, Inc. (VTYX) Q1 2023 Earnings Call Transcript
Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Raju Mohan - Founder & Chief Executive Officer Marty Auster - Chief Financial Officer Bill Sandborn - President & Chief Medical Officers Conference Call Participants Michael Yee - Jefferies Yasmeen Rahimi - Piper Sandler Derek Archila - Wells Fargo Alex Thompson - Stifel Chris Shibutani - Goldman Sachs Emily Bodnar - H.C. Wainwright Sam Slutsky - LifeSci Capital Operator Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences First Quarter 2023 Earnings Conference Call.
Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023
ENCINITAS, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2023 after market close on May 11, 2023. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress.
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
Where is the current bull market? All indications would be that it's in biotech!
Ventyx Biosciences Stock Flals Over 4%: Details
The stock price of Ventyx Biosciences Inc (NASDAQ: VTYX) fell by over 4% intraday today. This is why.
Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
ENCINITAS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference being held on March 30, 2023.
Ventyx Biosciences, Inc. (VTYX) Q4 2022 Earnings Call Transcript
Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Q4 2022 Earnings Conference Call March 24, 2023 4:30 PM ET Company Participants Raju Mohan - Founder & Chief Executive Officer Marty Auster - Chief Financial Officer Bill Sandborn - President & Chief Medical Officers Conference Call Participants Michael Yee - Jefferies Yasmeen Rahimi - Piper Sandler Jeff Jones - Oppenheimer Chris Shibutani - Goldman Sachs Emily Bodnar - H.C. Wainwright & Co Operator Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences Fourth Quarter and Full Year 2022 Earnings Conference Call.
Ventyx Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023
ENCINITAS, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the fourth quarter and full year 2022 after market close on March 23, 2023. Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress.
Recent Price Trend in Ventyx Biosciences, Inc. (VTYX) is Your Friend, Here's Why
Ventyx Biosciences, Inc. (VTYX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Ventyx Biosciences, Inc. (VTYX) Is a Great Choice for 'Trend' Investors, Here's Why
Ventyx Biosciences, Inc. (VTYX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Are You Looking for a Top Momentum Pick? Why Ventyx Biosciences, Inc. (VTYX) is a Great Choice
Does Ventyx Biosciences, Inc. (VTYX) have what it takes to be a top stock pick for momentum investors? Let's find out.
VTYX Financial details
VTYX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0 | |
| Net income per share | -2.18 | -2.32 | -7.39 | -2.06 | |
| Operating cash flow per share | -1.33 | -0.29 | -3.01 | -1.88 | |
| Free cash flow per share | -1.33 | -0.29 | -3.03 | -1.89 | |
| Cash per share | 0.16 | 0.01 | 20.16 | 6.06 | |
| Book value per share | -2.08 | -1.45 | -9.18 | -4.31 | |
| Tangible book value per share | -2.08 | -1.45 | 21.77 | 6.74 | |
| Share holders equity per share | -2.08 | -1.45 | -9.18 | -4.31 | |
| Interest debt per share | 2.01 | 0.62 | 0.01 | -0.06 | |
| Market cap | 41.8M | 443.94M | 254.72M | 1.72B | |
| Enterprise value | 45.34M | 456.35M | 183.93M | 1.66B | |
| P/E ratio | -9.66 | -9.07 | -2.69 | -15.94 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | |
| POCF ratio | -15.82 | -71.66 | -6.59 | -17.42 | |
| PFCF ratio | -15.82 | -71.66 | -6.55 | -17.37 | |
| P/B Ratio | -10.13 | -14.48 | -2.16 | -7.61 | |
| PTB ratio | -10.13 | -14.48 | -2.16 | -7.61 | |
| EV to sales | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -10.84 | -64.72 | -2.53 | -15.28 | |
| EV to operating cash flow | -17.16 | -73.66 | -4.76 | -16.78 | |
| EV to free cash flow | -17.16 | -73.66 | -4.73 | -16.73 | |
| Earnings yield | -0.1 | -0.11 | -0.37 | -0.06 | |
| Free cash flow yield | -0.06 | -0.01 | -0.15 | -0.06 | |
| Debt to equity | -1.08 | -1.01 | -0.1 | -0.08 | |
| Debt to assets | 12.83 | 126.12 | 0.04 | 0.05 | |
| Net debt to EBITDA | -0.85 | -1.76 | 0.98 | 0.58 | |
| Current ratio | 0.55 | 0.17 | 21.41 | 20.21 | |
| Interest coverage | -28.63 | -19.69 | -678.25 | 24.02 | |
| Income quality | 0.61 | 0.22 | 0.46 | 0.91 | |
| Dividend Yield | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.01 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | -8.73 | -0.59 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | |
| Graham number | 10.08 | 8.7 | 39.08 | 14.13 | |
| ROIC | 6.63 | 9.11 | -0.52 | -0.48 | |
| Return on tangible assets | -12.4 | -199.76 | -0.33 | -0.29 | |
| Graham Net | -2.1 | -1.45 | 19.2 | 5.73 | |
| Working capital | -282K | -1.16M | 250.74M | 314.33M | |
| Tangible asset value | -4.13M | -30.65M | 279.2M | 353.9M | |
| Net current asset value | -4.13M | -30.65M | 250.74M | 313.18M | |
| Invested capital | -0.93 | -0.41 | 0 | -0.01 | |
| Average receivables | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 732K | 2.88M | 5.55M | |
| Average inventory | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | |
| ROE | 1.05 | 1.6 | 0.8 | 0.48 | |
| Capex per share | 0 | 0 | -0.02 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.45 | -0.39 | -0.57 | -0.62 | -0.61 | |
| Operating cash flow per share | -0.25 | -0.29 | -0.46 | -0.83 | -0.54 | |
| Free cash flow per share | -0.25 | -0.29 | -0.47 | -0.84 | -0.54 | |
| Cash per share | 5.03 | 4.93 | 7.98 | 5.61 | 6.54 | |
| Book value per share | 5.12 | 4.78 | 7.42 | -3.99 | -4.6 | |
| Tangible book value per share | 5.12 | 4.78 | 7.42 | 6.24 | 6.45 | |
| Share holders equity per share | 5.12 | 4.78 | 7.42 | -3.99 | -4.6 | |
| Interest debt per share | 0.03 | 0.03 | 0.01 | -0.03 | -0.04 | |
| Market cap | 686.44M | 621.88M | 1.8B | 1.86B | 1.93B | |
| Enterprise value | 646.07M | 578.28M | 1.54B | 1.8B | 1.87B | |
| P/E ratio | -7.55 | -7.92 | -15.28 | -13.26 | -13.67 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -53.94 | -42.04 | -75.19 | -39.35 | -62.45 | |
| PFCF ratio | -53.78 | -41.96 | -74.89 | -39.26 | -62.33 | |
| P/B Ratio | 2.65 | 2.56 | 4.7 | -8.22 | -7.28 | |
| PTB ratio | 2.65 | 2.56 | 4.7 | -8.22 | -7.28 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -28.53 | -29.04 | -50.84 | -51.02 | -43.92 | |
| EV to operating cash flow | -50.77 | -39.09 | -64.28 | -38.01 | -60.43 | |
| EV to free cash flow | -50.62 | -39.02 | -64.02 | -37.92 | -60.32 | |
| Earnings yield | -0.03 | -0.03 | -0.02 | -0.02 | -0.02 | |
| Free cash flow yield | -0.02 | -0.02 | -0.01 | -0.03 | -0.02 | |
| Debt to equity | 0.07 | 0.08 | 0.1 | -0.08 | -0.07 | |
| Debt to assets | 0.07 | 0.07 | 0.09 | 0.05 | 0.05 | |
| Net debt to EBITDA | 1.78 | 2.19 | 8.62 | 1.8 | 1.46 | |
| Current ratio | 14.47 | 14.27 | 11.73 | 20.21 | 23.44 | |
| Interest coverage | 1.52K | 53.68 | 32.8 | 11.49 | 11.75 | |
| Income quality | 0.56 | 0.74 | 0.79 | 1.34 | 0.79 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.42 | -0.27 | -0.76 | -0.75 | -0.45 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 7.19 | 6.45 | 9.77 | 7.45 | 7.96 | |
| ROIC | -0.12 | -0.12 | 0.24 | -0.16 | -0.15 | |
| Return on tangible assets | -0.08 | -0.07 | -0.07 | -0.09 | -0.09 | |
| Graham Net | 4.66 | 4.55 | 7.27 | 5.3 | 6.24 | |
| Working capital | 239.71M | 234.52M | 382.73M | 314.33M | 370.54M | |
| Tangible asset value | 259.12M | 243.15M | 383.53M | 353.9M | 371.62M | |
| Net current asset value | 238.68M | 233.16M | 381.48M | 313.18M | 369.5M | |
| Invested capital | 0.01 | 0.01 | 0 | -0.01 | -0.01 | |
| Average receivables | 0 | 0 | 0 | 0 | 24.5K | |
| Average payables | 5.89M | 6.46M | 12.19M | 12.51M | 6.49M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.09 | -0.08 | -0.08 | 0.15 | 0.13 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
VTYX Frequently Asked Questions
What is Ventyx Biosciences, Inc. stock symbol ?
Ventyx Biosciences, Inc. is a US stock , located in Encinitas of Ca and trading under the symbol VTYX
Is Ventyx Biosciences, Inc. buy or a sell ?
4 stock analysts have 4 predictions with a medium analyst target price of $51.25. The lowest prediction is $45 and the highest is $60
What is VTYX stock prediction ?
What is Ventyx Biosciences, Inc. stock quote today ?
Ventyx Biosciences, Inc. stock price is $34.95 today.
Is Ventyx Biosciences, Inc. stock public?
Yes, Ventyx Biosciences, Inc. is a publicly traded company.
Company Profile
- Volume Average 845.65K
- Market Capitalization 1.99B
- Employee 76
- CEO Dr. Raju S. Mohan Ph.D.
- Headquarters Encinitas,CA,US
- IPO Date 2021-10-21
-
Website
https://www.ventyxbio.com 
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
